Previous 10 | Next 10 |
3 Under $1 Penny Stocks to Watch as April Ends If you’re looking for penny stocks to buy under $1, there are a few things you need to keep in mind. First, penny stocks that trade for less than $1 are often considered more volatile than their higher priced counterparts. That m...
Timber Pharmaceuticals (NYSE:TMBR) on Thursday said that the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to the company's lead asset TMB-001 for the treatment of severe subtypes of congenital ichthyosis, a family of rare genetic skin diseases highlighted by dry, t...
Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days BASKING RIDGE, NJ - ( NewMediaWire ) - April 28, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage bioph...
Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022 BASKING RIDGE, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on t...
Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype - BASKING RIDGE, NJ - ( NewMediaWire ) - March 25, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a b...
Basking Ridge, New Jersey--(Newsfile Corp. - February 28, 2022) - Timber Pharmaceuticals (NYSE American: TMBR) today announced that John Koconis, Chairman and CEO will be attending the Q1 Virtual Investor Summit. John Koconis, Chairman and CEO, will present a corporate overview, including ...
Timber Pharmaceuticals (TMBR -3.7%) said it had successful meeting with the U.S. Food and Drug Administration (FDA) that resulted in a clear path to progress to a phase 3 study of its lead asset TMB-001. The company said it had completed a phase 2b CONTROL study evaluating topical TMB-00...
- Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference - - Company plans to initiate Phase 3 study in second quarter of 2022 - BASKING RIDGE, NJ - ( NewMediaWire ) - February 03, 2022 - Timber Pharmaceuticals, Inc. ("Timber" or the “Comp...
Virtual Conference on January 10-13, 2022 BASKING RIDGE, NJ, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commerc...
Call to be held on Monday, November 22 nd at 10:00am ET BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the devel...
News, Short Squeeze, Breakout and More Instantly...
Timber Pharmaceuticals Inc. Company Name:
TMBR Stock Symbol:
NYSE Market:
Timber Pharmaceuticals Inc. Website:
WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that...
WARREN, NJ - ( NewMediaWire ) - November 28, 2023 - Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-...
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated d...